Truist Securities Maintains Hold on GoodRx Holdings, Raises Price Target to $7
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst Jailendra Singh has maintained a 'Hold' rating on GoodRx Holdings (NASDAQ:GDRX) and raised the price target from $6 to $7.
July 18, 2023 | 2:03 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
GoodRx Holdings' price target has been raised from $6 to $7 by Truist Securities, while maintaining a 'Hold' rating.
The news is directly about GoodRx Holdings. The 'Hold' rating suggests that the analyst does not expect significant price movement in the short term. However, the increase in price target could be seen as a positive signal, potentially leading to a slight increase in the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100